Toll Brothers
TOL
Meritage Homes
MTH
Taylor Morrison Home
TMHC
D.R. Horton
DHI
KB Home
KBH
US Stock MarketDetailed Quotes
TNGX Tango Therapeutics
- 3.230
- -0.240-6.92%
Close Jan 8 16:00 ET
- 3.230
- 0.0000.00%
Post 20:01 ET
346.96MMarket Cap-2.81P/E (TTM)
3.460High3.115Low734.78KVolume3.460Open3.470Pre Close2.38MTurnover1.58%Turnover RatioLossP/E (Static)107.42MShares13.00552wk High1.51P/B149.93MFloat Cap2.70052wk Low--Dividend TTM46.42MShs Float18.840Historical High--Div YieldTTM9.94%Amplitude2.470Historical Low3.234Avg Price1Lot Size
About Tango Therapeutics Company
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.
Company Profile
SymbolTNGX
Company NameTango Therapeutics
Listing DateSep 3, 2020
Issue Price10.00
Founded2017
CEODr. Barbara L. Weber, M.D.
MarketNASDAQ
Employees140
Fiscal Year Ends12-31
Address201 Brookline Avenue,Suite 901
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02215
Phone1-857-320-4900
Websitehttp://www.tangotx.com
Company Executives
- Name
- Position
- Salary
- Dr. Barbara L. Weber, M.D.
- President, Chief Executive Officer and Director
- 3.39M
- Douglas Barry
- General Counsel, Chief Compliance Officer and Corporate Secretary
- --
- Julie Carretero
- Chief Human Resources Officer
- --
- Daniella Beckman
- Chief Financial Officer
- 1.52M
- Alexis A. Borisy, A.M.
- Chairman of the Board
- 171.53K
- Dr. Adam Crystal, M.D.,PhD
- President, Research and Development
- 3.11M
- Kanishka Pothula
- Independent Director
- --
- Lesley Ann Calhoun
- Independent Director
- 148.03K
- Dr. Malte Peters, M.D.
- Independent Director
- 139.03K
- Dr. Mace Rothenberg, M.D.
- Independent Director
- 141.53K
- John B. Ketchum
- Independent Director
- 375.87K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.